Clinical Trials Logo
  1. Home
  2. Diffuse Large B-Cell Lymphoma
  3. NCT06031194
  4. Details
NCT06031194 Clinical Trial

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma Clinical Trial

Official title:
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06031194
Other study ID # OSU-22305
Secondary ID NCI-2023-03467
Status Recruiting
Phase
First received
Last updated
Start date May 10, 2023
Est. completion date December 31, 2024

Study information
Verified date October 2023
Source Ohio State University Comprehensive Cancer Center
Contact The Ohio State Comprehensive Cancer Center
Phone 800-293-5066
Email OSUCCCClinicaltrials@osumc.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

Description:

PRIMARY OBJECTIVES: I. To identify SNPs associated with delayed MTX clearance. II. To explore any association between SNPs and increased toxicity. OUTLINE: This is an observational study. Participants undergo blood sample collection and have their medical records reviewed on study.

Recruitment information / eligibility
Status Recruiting
Enrollment 20
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - * Adult (age = 18 years at diagnosis) - Diagnosis of DLBCL or PCNSL - Planned to undergo treatment with HDMTX (= 3 g/m^2) at the James Cancer Hospital. Note: patients with CKD are eligible to participate regardless of eGFR provided the treating physician is planning a dose of HDMTX of at least 3 g/ m^2. - Ability to provide informed consent. Exclusion Criteria: - * Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation - Pregnancy (positive serum or urine pregnancy test), lactating or breast feeding - Prisoners or incarcerated patients - Total bilirubin > 5 mg/dL

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Non-Interventional Study
Non-interventional study

Locations
Country Name City State
United States Ohio State University Comprehensive Cancer Center Columbus Ohio

Sponsors (1)
Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary SNPs (single nucleotide polymorphisms) associated with delayed MTX clearance Determine the SNPs associated with delayed methotrexate clearance Up to 24 weeks
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05823701 - Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients Phase 2
Completed NCT01691898 - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Recruiting NCT03656835 - Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma N/A
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Active, not recruiting NCT02060656 - Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) Phase 2
Active, not recruiting NCT01653067 - STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma Phase 2
Enrolling by invitation NCT00846157 - Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Phase 3
Completed NCT00440583 - The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP Phase 2
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Recruiting NCT04981795 - realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Completed NCT01186978 - Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma N/A
Completed NCT01197560 - Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Phase 2/Phase 3
Recruiting NCT03246906 - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Phase 2
Not yet recruiting NCT05990985 - The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. N/A
Completed NCT02890602 - Erythropoietin for Management of Anemia Caused by Chemotherapy Phase 2
Completed NCT03630159 - Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients Phase 1
Active, not recruiting NCT04529772 - A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) Phase 3
Active, not recruiting NCT02900651 - Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Phase 1
Active, not recruiting NCT02481310 - Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Phase 1/Phase 2

External Links